Literature DB >> 11692029

Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations.

E Kilic1, M Bähr, D M Hermann.   

Abstract

BACKGROUND AND
PURPOSE: It has been suggested that recombinant tissue plasminogen activator (rtPA) may cause an aggravation of injury after transient focal ischemia via excitotoxic side effects. Such rtPA toxicity would be of major clinical significance since rtPA is increasingly used in stroke treatment. This study was conducted to evaluate the effects of dose, application time, and hemodynamic changes after intravenous rtPA treatment in focal ischemia.
METHODS: Mice were subjected to a 90-minute episode of middle cerebral artery thread occlusion, and rtPA effects were assessed by laser-Doppler flowmetry, [(14)C]iodoantipyrine autoradiography, and triphenyltetrazolium chloride staining. RESULTS AND
CONCLUSIONS: We provide evidence that rtPA provokes complex hemodynamic alterations in the ischemic brain tissue, which include an initial hyperperfusion and a more delayed hypoperfusion response. Changes are most pronounced in the periphery of the ischemic infarct, where regional blood flow drops below critical thresholds of tissue viability. Our observations suggest that changes of perfusion may at least partly explain the rtPA-induced increase of infarct size, which has previously been reported and which we also confirmed in the present experiments. Notably, both the secondary hypoperfusion and increase of infarct volume were abolished when rtPA-treated animals received additional heparin infusions. This finding suggests that a secondary hypercoagulability may compromise brain perfusion after rtPA delivery. Accordingly, early treatment with heparin might help to prevent the rtPA-induced changes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692029     DOI: 10.1161/hs1101.097381

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

Review 1.  The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.

Authors:  George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

Review 2.  Adult neural stem cells: response to stroke injury and potential for therapeutic applications.

Authors:  Basam Z Barkho; Xinyu Zhao
Journal:  Curr Stem Cell Res Ther       Date:  2011-12       Impact factor: 3.828

3.  Cerebral blood flow alteration in neuroprotection following cerebral ischaemia.

Authors:  Brad A Sutherland; Michalis Papadakis; Ruo-Li Chen; Alastair M Buchan
Journal:  J Physiol       Date:  2011-06-27       Impact factor: 5.182

Review 4.  Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.

Authors:  Chengli Liu; Jie Xie; Shanshan Sun; Hui Li; Tianyu Li; Chao Jiang; Xuemei Chen; Junmin Wang; Anh Le; Jiarui Wang; Zhanfei Li; Jian Wang; Wei Wang
Journal:  Cell Mol Neurobiol       Date:  2020-10-30       Impact factor: 5.046

5.  Modulation of gene expression on a transcriptome-wide level following human neural stem cell transplantation in aged mouse stroke brains.

Authors:  Milton H Hamblin; Rabi Murad; Jun Yin; Gustavo Vallim; Jean-Pyo Lee
Journal:  Exp Neurol       Date:  2021-11-06       Impact factor: 5.330

6.  Phosphodiesterase 10A Is a Critical Target for Neuroprotection in a Mouse Model of Ischemic Stroke.

Authors:  Mustafa C Beker; Ahmet B Caglayan; Serdar Altunay; Elif Ozbay; Nilay Ates; Taha Kelestemur; Berrak Caglayan; Ulkan Kilic; Thorsten R Doeppner; Dirk M Hermann; Ertugrul Kilic
Journal:  Mol Neurobiol       Date:  2021-11-04       Impact factor: 5.590

Review 7.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

8.  A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis.

Authors:  Arunmozhiarasi Armugam; Charmian D N Cher; KaiYing Lim; Dawn C I Koh; David W Howells; Kandiah Jeyaseelan
Journal:  BMC Neurosci       Date:  2009-09-23       Impact factor: 3.288

9.  Alteplase treatment does not increase brain injury after mechanical middle cerebral artery occlusion in the rat.

Authors:  Brad A Sutherland; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-21       Impact factor: 6.200

10.  The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.

Authors:  Silvia Goebel; Zhongmin Li; Jasmin Vogelmann; Hans-Peter Holthoff; Heidrun Degen; Dirk M Hermann; Meinrad Gawaz; Martin Ungerer; Götz Münch
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.